427 related articles for article (PubMed ID: 25607821)
21. Interstrain differences in susceptibility to non-alcoholic steatohepatitis.
Yamazaki Y; Kakizaki S; Takizawa D; Ichikawa T; Sato K; Takagi H; Mori M
J Gastroenterol Hepatol; 2008 Feb; 23(2):276-82. PubMed ID: 17868334
[TBL] [Abstract][Full Text] [Related]
22. Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient l-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model.
Nakanishi K; Kaji K; Kitade M; Kubo T; Furukawa M; Saikawa S; Shimozato N; Sato S; Seki K; Kawaratani H; Moriya K; Namisaki T; Yoshiji H
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31163617
[TBL] [Abstract][Full Text] [Related]
23. Development of a novel mouse model of hepatocellular carcinoma with nonalcoholic steatohepatitis using a high-fat, choline-deficient diet and intraperitoneal injection of diethylnitrosamine.
Kishida N; Matsuda S; Itano O; Shinoda M; Kitago M; Yagi H; Abe Y; Hibi T; Masugi Y; Aiura K; Sakamoto M; Kitagawa Y
BMC Gastroenterol; 2016 Jun; 16(1):61. PubMed ID: 27296438
[TBL] [Abstract][Full Text] [Related]
24. Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice.
Susutlertpanya W; Wakuda H; Otani N; Kuramoto T; Li L; Kuranari M; Sekiguchi A; Kudo H; Uchida T; Imai H; Uemura N
Life Sci; 2019 Jul; 228():251-257. PubMed ID: 31078545
[TBL] [Abstract][Full Text] [Related]
25. Morphological and functional characterization of non-alcoholic fatty liver disease induced by a methionine-choline-deficient diet in C57BL/6 mice.
Itagaki H; Shimizu K; Morikawa S; Ogawa K; Ezaki T
Int J Clin Exp Pathol; 2013; 6(12):2683-96. PubMed ID: 24294355
[TBL] [Abstract][Full Text] [Related]
26. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
Hayashizaki-Someya Y; Kurosaki E; Takasu T; Mitori H; Yamazaki S; Koide K; Takakura S
Eur J Pharmacol; 2015 May; 754():19-24. PubMed ID: 25701721
[TBL] [Abstract][Full Text] [Related]
27. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.
Dongiovanni P; Meroni M; Baselli GA; Bassani GA; Rametta R; Pietrelli A; Maggioni M; Facciotti F; Trunzo V; Badiali S; Fargion S; Gatti S; Valenti L
Clin Sci (Lond); 2017 Jun; 131(12):1301-1315. PubMed ID: 28468951
[TBL] [Abstract][Full Text] [Related]
28. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
Nakatsu Y; Seno Y; Kushiyama A; Sakoda H; Fujishiro M; Katasako A; Mori K; Matsunaga Y; Fukushima T; Kanaoka R; Yamamotoya T; Kamata H; Asano T
Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G42-51. PubMed ID: 25999428
[TBL] [Abstract][Full Text] [Related]
29. Total aralosides of aralia elata (Miq) seem (TASAES) ameliorate nonalcoholic steatohepatitis by modulating IRE1α-mediated JNK and NF-κB pathways in ApoE-/- mice.
Luo Y; Dong X; Yu Y; Sun G; Sun X
J Ethnopharmacol; 2015 Apr; 163():241-50. PubMed ID: 25655997
[TBL] [Abstract][Full Text] [Related]
30. Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice.
Yokohama K; Fukunishi S; Ii M; Nakamura K; Ohama H; Tsuchimoto Y; Asai A; Tsuda Y; Higuchi K
Int J Mol Med; 2016 Nov; 38(5):1499-1506. PubMed ID: 28025996
[TBL] [Abstract][Full Text] [Related]
31. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
[TBL] [Abstract][Full Text] [Related]
32. Nonalcoholic steatohepatitis-associated hepatocarcinogenesis in mice fed a modified choline-deficient, methionine-lowered, L-amino acid-defined diet and the role of signal changes.
Suzuki-Kemuriyama N; Abe A; Nakane S; Yuki M; Miyajima K; Nakae D
PLoS One; 2023; 18(8):e0287657. PubMed ID: 37535625
[TBL] [Abstract][Full Text] [Related]
33. Oral Administration of Mulberry (
Wakame K; Sato K; Kasai M; Kikuchi E; Shimizu K; Kudo A; Komatsu KI; Nakata A
Anticancer Res; 2022 Aug; 42(8):4055-4062. PubMed ID: 35896224
[TBL] [Abstract][Full Text] [Related]
34. [Establishment and evaluation of a mouse model of nonalcoholic steatohepatitis-related hepatocellular carcinoma].
Luo Y; Yang WJ; Chen JY; Zhang J; Zeng XD; Zhuang ZJ; Zang SF; Zhou G; Di CH; Shi JP
Zhonghua Gan Zang Bing Za Zhi; 2016 Apr; 24(4):279-84. PubMed ID: 27470627
[TBL] [Abstract][Full Text] [Related]
35. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis.
Asano T; Watanabe K; Kubota N; Gunji T; Omata M; Kadowaki T; Ohnishi S
J Gastroenterol Hepatol; 2009 Oct; 24(10):1669-76. PubMed ID: 19788607
[TBL] [Abstract][Full Text] [Related]
36. Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model.
Nozaki Y; Fujita K; Wada K; Yoneda M; Kessoku T; Shinohara Y; Imajo K; Ogawa Y; Nakamuta M; Saito S; Masaki N; Nagashima Y; Terauchi Y; Nakajima A
BMC Gastroenterol; 2015 Apr; 15():42. PubMed ID: 25881230
[TBL] [Abstract][Full Text] [Related]
37. A mouse model for nonalcoholic steatohepatitis.
Sundaresan S; Vijayagopal P; Mills N; Imrhan V; Prasad C
J Nutr Biochem; 2011 Oct; 22(10):979-84. PubMed ID: 21190824
[TBL] [Abstract][Full Text] [Related]
38. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model.
Kamada Y; Matsumoto H; Tamura S; Fukushima J; Kiso S; Fukui K; Igura T; Maeda N; Kihara S; Funahashi T; Matsuzawa Y; Shimomura I; Hayashi N
J Hepatol; 2007 Oct; 47(4):556-64. PubMed ID: 17459514
[TBL] [Abstract][Full Text] [Related]
39. Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice.
Honda T; Ishigami M; Luo F; Lingyun M; Ishizu Y; Kuzuya T; Hayashi K; Nakano I; Ishikawa T; Feng GG; Katano Y; Kohama T; Kitaura Y; Shimomura Y; Goto H; Hirooka Y
Metabolism; 2017 Apr; 69():177-187. PubMed ID: 28285648
[TBL] [Abstract][Full Text] [Related]
40. Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model.
Morishita A; Tadokoro T; Fujihara S; Iwama H; Oura K; Fujita K; Tani J; Takuma K; Nakahara M; Shi T; Haba R; Okano K; Nishiyama A; Ono M; Himoto T; Masaki T
PLoS One; 2022; 17(2):e0261310. PubMed ID: 35192632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
